other types of delivery- peptides/proteins Flashcards

1
Q

what is the problem with delivering protein

A

large hydrophilic molecules, extravascular access is hard, poor stability, hard to absorb, complex pharmacological action

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

size and shape of macromolecules and proteins

A

macromolecules have limited size, molecular weight and size relationship depends on shape, proteins usually globular and tightly packed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

the amount of macromolecules reaching tissues are affected by

A

rate of elimination by kidneys and metabolism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

how are macromolecules eliminated

A

kidney filtration

small proteins are eliminated from kidney by glomerular filtration, larger molecules are not

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

how are small proteins eliminated from the kidney

A

glomerular filtration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what are macromolecules

A

molecule containing lots of atoms eg. protein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

why are proteins needed as drugs/medicine

A

to meet unmet conditions idk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

properties of protein and peptide drugs

A

large hydrophilic molecule (0.5-100kDa), not well transported across biological membrane, <2% bioavailability, instabilities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

describe the physical instability of protein/peptide drugs

A

proteins can easily lose their 3d structure (secondary, tertiary, quaternary denaturation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what causes physical instability of protein/peptide drugs

A

hydrophobic conditions, surfactants, pH, solvent, temperature, dehydration, lyophilisation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

results of physical instability in protein/peptide drugs

A

adsorption- at interfaces
aggregation/precipitation- denatured unfolded proteins interact

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

main processes of chemical instability in protein/peptide drugs

A

deamidation- asparagine and glutamine residues hydrolysed to form a carboxylic acid

oxidation- methionine, cysteine, oxygen in air, oxygen radical, catalysed by transition metal, peroxide formation

photo-oxidation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

comment on the biological stability of protein/peptide drugs

A

hydrolysed into amino acids and small peptides by GI tract, very few are stable to biodegradation

gastric acid causes denaturation

small intestine

colon- less digestive enzymes, substantial microbial enzymes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

roles of additives in preformulation of protein/peptide drugs

A

salts- decrease denaturation by binding to protein

polyalcohol- stabilise by selective solvation

surfactants- prevent adsorption of proteins at surfaces and aggregation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

chemical modifications of proteins

A

synthetic polymers or lipids covalently bound to proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

primary sequence alterations of proteins

A

specific amino acid can be changed, improves physical and chemical stability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

why chemically modify proteins

A

control pharmacokinetics and pharmacodynamics through the formulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

describe the routes of administration of protein/peptide drugs

A

parenteral- only practical method for most, intravenous/subcutaneous/intramuscular

non parenteral- highly desirable, oral is best, low absorption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

advantages and disadvantages of parenteral delivery in protein/peptide drugs

A

advantages- controlled drug release, improves therapeutic index, protects from unwanted drug disposition, extravascular access

disadvantages- particulate system but particles cant cross vascular endothelium, soluble carrier systems have transport/stability problems

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

types of implantables

A

polymer gel matrix, polymer fibre system, osmotic mini pump, tablet type implants, automatic feedback system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

how do implantables work

A

delivered through intramuscular or subcutaneous route

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

chronobiological effects of protein/peptide drugs

A

zero order controlled released may not be optimal, pulsatile or complex delivery kinetics is beneficial sometimes, optimal pattern for delivery unknown, non zero order delivery difficult to produce

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

oral delivery of proteins

A

avoids acidic pH and proteolysis

24
Q

problems with using protein/peptide drugs

A

physiological barriers and stability is big issue

25
what is topical delivery
delivery of drugs on surface of skin, local action, skin diseases
26
what is transdermal delivery
delivery of drugs across/through skin, maximises systemic absorption, drug target in body
27
describe skin structure and function
subcutaneous tissue- adipose tissue, fat insulates and prevents mechanical shock, rich blood supply, nerves dermis- collagen/elastin in mucopolysaccharide gel, nerve endings, sweat and sebaceous glands, low drug conc drugs due to rich blood supply, conc gradient drives drug penetration, drug taken away quickly, lots of water, high aqueous environment epidermis- keratinocytes differentiates to form corneocytes, Langerhans cells, melanocytes
28
what do melanocytes do
produce melanin
29
different routes drugs get transported into skin
intracellular route- stratum corneum intercellular route- main route shunt route- minor route
30
drug properties that affect permeation
drug conc in vehicle partition coefficient- must be soluble in both oil and water to pass through layers lipophilic drugs more likely to pass through than hydrophilic- if too lipophilic slow permeation molecular weight- small penetrate faster drug structure- hydrogen bonding to skin constituents, pKa causes drug to diffuse into unionised form, unionised is better
31
ideal drug properties for a transdermal drug
Log P between 1-4 max molecular weight <500 (low dose is ok) daily dose 10-20mg, flux 1mg/cm^2 per day, patch size 20cm^2 unionised at pH of skin
32
why is it better for transdermal drugs to be unionised at pH of skin
ionised/charged+ more polar so the intercellular route is less of an option
33
adhesive patches for transdermal delivery
designed for constant controlled release over an extended period of time, avoids first pass metabolism, liner adhesive and backing layer, low delivery efficiency
34
biological factors of transdermal delivery
specify where to apply patch, skin age affects permeability, skin conditions (injury, solvents, disease, hydration), site of application (variation of stratum corneum thickness), skin metabolism, penetration enhancers
35
common targets of topical delivery
surface microorganisms, nail, hair, stratum corneum, viable epidermis and dermis
36
functions of a good topical formulation
cleansing, lubricant, emollient action
37
formulations of topical delivery
complex multicomponent base needed- aqueous bas, thickening/emulsifying agents vehicle cosolvents enhance permeability and partition into skin buffer/antioxidant/preservatives
38
formulation designs of topical delivery
thin film, open to atmosphere changes in use, short acting, variable delivery rate, low delivery efficiency
39
factors that affect topical delivery
application of film, diffusion of drug through vehicle, partitioning of drug from vehicle into skin, partitioning of drug from stratum corneum into viable epidermis, diffusion of drug across skin membrane
40
what is the main barrier of permeation of drugs on skin
stratum corneum
41
use of topical delivery
skin disease
42
use of transdermal delivery
systemic delivery
43
formulation types of transdermal/topical
transdermal patches, creams, ointments, gels
44
what does gingival mean
on gums
45
what does sublingual mean
under tongue
46
what does buccal mean
mucosa of mouth, often inside cheek or behind lips
47
issues with buccal and sublingual
wet layer with mucin on surface. structure of mucosa shows epithelial tissue like skin, some keratinised epithelium but thickness and keratinisation varies
48
common targets of buccal and sublingual conditions
mouth ulcers, sore throat, gum disease, breath freshening, infections, dry mouth, angina, analgesia
49
benefits of buccal and sublingual delivery
easy/convenient to administer, easy removal if theres side effects, direct route to systemic circulation avoids first pass metabolism in liver and enzymatic degradation in GI tract, fast action
50
how is drug absorbed by in buccal and sublingual delivery
passive diffusion
51
relative permeability for buccal and sublingual delivery
sublingual>buccal>external skin
52
sublingual mucosa structure
thin membrane, large veins, rapid absorption and good bioavailability
53
what type of drugs has the best absorption and bioavailability and why
lipid soluble drugs with small dose, avoids large 1st pass effect, better predictability of dose
54
formulation designs of buccal and sublingual delivery
palatable- taste masking, flavouring for patient compliance buccal dose form- formulated to stick ot mucosa otherwise it might be swallowed, viscous polymer, bioadhesive polymer, design to erode slowly sublingual tablet- designed to dissolve rapidly for fast and rapid absorption/effect
55
types of buccal and sublingual delivery designs
lozenges- sugar/sorbitol glass/compressed tablets, suck to release active agent (like strepsils) gels-polymers mouthwash- solution/suspension to rise in mouth polymer patches- adhesive hydrogel disc
56